| Congresso Brasileiro de Microbiologia 2023 | Resumo: 666-1 | ||||
Resumo:There is a growing concern about fungal infections, mainly due to the increasingly development of resistance to commercially available antifungal drugs. In addition, there is a low variety of antifungals currently available on the market. Fungi of the genus Candida are known to be opportunistic pathogens, causing local or even systemic infections. Given the clinical importance of these infections, the search for new antifungal therapeutics is essential. This study aimed to evaluate the action of photoactivated cationic porphyrins on different Candida isolates obtained from denture stomatitis lesions, and reference strains. Eight clinical isolates of Candida were obtained from patients bearing denture stomatitis lesions; these isolates were identified using a method based on mass spectrometry (Biotyper). In addition to these, three reference strains were also tested. Sensitivity tests were performed using the broth microdilution technique using commercial antifungals or cationic porphyrins; the concentrations ranged from 0.125 to 75 μg/mL for fluconazole, 0.313 to 16 μg/mL for ketoconazole, itraconazole and nystatin, and 0.1465 to 75 μM/mL for the porphyrins. Among the four antifungals tested, the strains were less susceptible to fluconazole, being more susceptible to itraconazole and ketoconazole; nystatin had a fungicidal effect on all the analyzed strains. In the susceptibility tests using the cationic porphyrin 3H2TmeP+, total fungistatic effects (100%) were found in all analyzed strains (reference strains and clinical isolates). Regarding the fungicidal effect, all strains were 100% inactivated by the porphyrins in low concentrations. Thus, it is possible to verify the possible applicability of photoactivated porphyrins in treatments for candidiasis, especially denture stomatitis, as it was a microbial agent capable of inhibiting the growth and inactivating clinical isolates with low sensitivity to commercial antifungals. Palavras-chave: antimicrobials, antifungals, candidiasis, photoinactivation Agência de fomento:Fundação de Amparo à Pesquisa e Extensão (FAPEX) | |||||